Monday, 16 Sep 2019

You are here

Alpha-1-Anti-Trypsin-Fc Fusion Protein Ameliorates Gouty Arthritis

Gout is the most common inflammatory arthritis affecting adults and, probably, one of the most underestimated.

Besides damaging joints and causing significant pain and disability, there are pathogenic mechanisms by which uric acid participates in the development of numerous comorbidities - including cardiovascular disease. 
 
Prevention and early treatment of acute gout not only decreases the disability and economic burden associated with it, but may also lessen the impact of CV and other comorbidities. Hence, finding new ways to quickly and effectively resolve acute flares of gout could be priceless.
 
Joosten et al has generated a new protein, recombinant human alpha-1-anti-trypsin (AAT)-IgG1 Fc fusion protein (AAT-Fc), to evaluate its antiinflammatory potential in and IL-1 induced animal model of gouty arthritis. A single low dose of AAT-Fc was shown to be highly effective in reducing joint inflammation in an animal model of acute gouty arthritis. Considering the long-term safety of plasma-derived AAT use in humans, subcutaneous AAT-Fc may emerge as a promising therapy for gout attacks.
Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Modifiable Risk Factors for Hyperuricemia

Choi and colleagues have shown that four modifiable risk factors (BMI, the DASH diet, alcohol use, and diuretic use) could individually account for a notable proportion of observed hyperuricemia. 

Researchers examine modifiable risk factors for hyperuricemia and how this could be prevented through risk factor modification in the general population.

Opioids Overused in Acute Gout

Opioids were commonly given to patients as a treatment for acute gout attacks, despite the availability of other effective and appropriate therapies, a retrospective study found.

Allopurinol Fails to Curtail Hypertension

Editor's note: July 1 - 5, RheumNow is running the best of the EULAR 2019 meeting. A novel trial presented at EULAR 2019 last week assessed whether the use of urate-lowering therapy (ULT) would control hypertension in those at risk; however, results of this trial were largely negative.

Hypertension is one of the many comorbidities that plagues gout patients.

Allopurinol Fails to Curtail Hypertension

A novel trial presented at EULAR 2019 last week assessed whether the use of urate-lowering therapy (ULT) would control hypertension in those at risk; however, results of this trial were largely negative.

Hypertension is one of the many comorbidities that plagues gout patients.

Updated 2018 EULAR Recommendations for the Diagnosis of Gout

The first EULAR recommendations for the diagnosis of gout were published in 2006. A task force was formed and following a systematic review, they voted unanimously for changes in all items of the 2006 recommendations.